1. Home
  2. SSYS vs DRUG Comparison

SSYS vs DRUG Comparison

Compare SSYS & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stratasys Ltd. (Israel)

SSYS

Stratasys Ltd. (Israel)

N/A

Current Price

$8.56

Market Cap

892.8M

Sector

Technology

ML Signal

N/A

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

N/A

Current Price

$80.76

Market Cap

856.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SSYS
DRUG
Founded
1989
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Pharmaceuticals and Biotechnology
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
892.8M
856.4M
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
SSYS
DRUG
Price
$8.56
$80.76
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$12.33
$124.00
AVG Volume (30 Days)
865.9K
73.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.69
N/A
Revenue Next Year
$6.09
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.12
$23.18
52 Week High
$12.78
$123.75

Technical Indicators

Market Signals
Indicator
SSYS
DRUG
Relative Strength Index (RSI) 30.32 48.24
Support Level $8.34 $77.80
Resistance Level $11.43 $91.00
Average True Range (ATR) 0.47 4.77
MACD -0.20 -0.62
Stochastic Oscillator 11.74 40.88

Price Performance

Historical Comparison
SSYS
DRUG

About SSYS Stratasys Ltd. (Israel)

Stratasys Ltd is a polymer-based 3D printing solution, which provides a product life cycle, with multiple technologies and complete solutions for superior application fit, across industrial, healthcare, and consumer fields. It focuses, in particular, on polymer 3D printing solutions that address the fastest-growing manufacturing solutions viewed as the potential growth opportunity in the 3D printing industry. Its printers include FDM, PolyJet, Stereolithography, P3, and SAF. Its software is GrabCAD Software, Connectivity, Digital Anatomy Creator, and OpenAM Software. It generates revenue through 3D printing systems, related services, and consumables and by providing additive manufacturing solutions.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: